Document is current
Any future updates will be listed below
-
Authors
Osaka, Kimito
Kishida, Takeshi
Umemoto, Susumu
Karashima, Takashi https://orcid.org/0000-0001-7338-8059
Nakagawa, Masatoshi
Yoshida, Eisaku
Yoshimura, Toru
Sakaguchi, Masahiko
Inoue, Keiji
Koshikawa, Naohiko
Seiki, Motoharu
Shuin, Taro
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (5lm0103002j0004 (B29))
Research funding from Abbott Laboratories
- License Information
-
More Information
Article History
Received: 25 February 2025
Accepted: 26 January 2026
First Online: 2 February 2026
Declarations
:
: The study protocol was approved by our institutional review board (Kochi Medical School Hospital: ERB-106289; Kanagawa Cancer Center: 2019–22).
: All patients provided written informed consent and consented to publication.
: T. Yoshimura, E. Yoshida and M. Nakagawa are employees of Abbott Japan LLC. K. Inoue received patent royalties and research funds from SBI Pharmaceuticals Co., Ltd., honoraria from Chugai Pharmaceutical Co., Ltd., and endowments from Astellas Pharma Inc., Takeda Pharmaceutical Co., Ltd., MC Medical Inc. and Ono Pharmaceutical Co., Ltd. M. Seiki and N. Koshikawa received research funds from Tokyo University. N. Koshikawa, T. Karashima and T. Shuin received research funds from Abbott Japan LLC. None of the other authors have any potential conflicts of interest.
